Trial Profile
The prospective study of blood biomarker and gut microbiota in the patients treated with anti-PD 1 antibody for advanced non-small cell lung cancer
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 11 Mar 2020
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Pharmacodynamics
- 08 Mar 2020 Planned End Date changed from 30 Sep 2019 to 30 Sep 2023.
- 22 Mar 2019 Planned End Date changed from 30 Apr 2019 to 30 Sep 2019.
- 26 Apr 2017 Status changed from not yet recruiting to recruiting.